ArticleJournal of medicinal chemistry2022
Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria.
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.Infection · 2026Review
- DifferentialMicrobiology spectrum · 2025Article
- The Importance of Murine Models in Determining In Vivo Pharmacokinetics, Safety, and Efficacy in Antimalarial Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Malaria's Achilles' Heels: A Review of Plasmodium Life Cycle Vulnerabilities for Drug Discovery.Current topics in medicinal chemistry · 2025Review
- Innovations in Antimalarial Drug Discovery: New Targets and Leads.Current drug targets · 2025Review
- The possibilities and challenges associated with selective targetingTransactions of the Royal Society of South Africa. Royal Society of South Africa · 2025Article
- Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.ACS infectious diseases · 2024Article
- Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials.Nature communications · 2024Article
- An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.Antimicrobial agents and chemotherapy · 2024Article
- Defining the next generation of severe malaria treatment: a target product profile.Malaria journal · 2024Review
- A pH Fingerprint Assay to Identify Inhibitors of Multiple Validated and Potential Antimalarial Drug Targets.ACS infectious diseases · 2024Article
- Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023Review
- Editorial: Antimalarial chemotherapy in the XXIst century, volume II.Frontiers in pharmacology · 2023Article
- A G358S mutation in the Plasmodium falciparum NaNature communications · 2022Article
- Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment.Trends in parasitology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 10 institutions in 7 countries.
Benjamin R TaftGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.ORCID 0000-0002-1129-7618
Fumiaki YokokawaGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.ORCID 0000-0002-2861-9281
Tom KirraneGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Anne-Catherine MataGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Richard HuangGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Nicole BlaquiereGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Grace WaldronGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Bin ZouNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Oliver SimonNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Subramanyam VankadaraNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Wai Ling ChanNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Mei DingNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Sandra SimNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Judith StraimerNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Armand GuiguemdeNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Suresh B LakshminarayanaNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Jay Prakash JainNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Christophe BodenreiderNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Christopher ThompsonNovartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Christian LanshoeftNovartis Institutes for Biomedical Research, Fabrikstrasse 14, Basel CH-4056, Switzerland.ORCID 0000-0002-2405-0227
Wei ShuGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Eric FangChemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Jafri QumberNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Katherine ChanNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Luying PeiNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Yen-Liang ChenNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Hanna SchulzNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Jessie LimNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Siti Nurdiana AbasNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Xiaoman AngNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Yugang LiuTechnical Research and Development, Global Drug Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936, United States.
Iñigo Angulo-BarturenThe Art of Discovery, Astondo Bidea, BIC Bizkaia building, no. 612 Derio 48160 Bizkaia, Basque Country, Spain.
María Belén Jiménez-DíazThe Art of Discovery, Astondo Bidea, BIC Bizkaia building, no. 612 Derio 48160 Bizkaia, Basque Country, Spain.
Francisco Javier GamoTres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.ORCID 0000-0002-1854-2882
Benigno Crespo-FernandezTres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain.
Philip J RosenthalDepartment of Medicine, University of California, 533 Parnassus Avenue, San Francisco, California 94143, Unites States.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States.
Patrick TumwebazeInfectious Diseases Research Collaboration, Plot 2C Nakasero Hill Road, P.O. Box 7475 Kampala, Uganda.
Anna Caroline Campos AguiarSão Carlos Institute of Physics, University of São Paulo, São Carlos, São Paulo 13563-120, Brazil.
Brice CampoMedicines for Malaria Venture, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland.
Simon CampbellMedicines for Malaria Venture, 20 Route de Pre-Bois, 1215 Geneva 15, Switzerland.
Jürgen WagnerNovartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670, Singapore.
Thierry T DiaganaNovartis Institute for Tropical Diseases, 5959 Horton Street, Emeryville, California 94608, United States.
Christopher SarkoGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, 5959 Horton Street, Emeryville, California 94608, United States.
Novartis (Singapore) · SGNovartis (United States) · USEuskadiko Parke Teknologikoa · ESGlaxoSmithKline (France) · FRMedicines for Malaria Venture · CHDominican University of California · USInfectious Diseases Research Collaboration · UGNovartis (Switzerland) · CHUniversidade Federal de São Carlos · BRUniversity of California, San Francisco · US
Funding
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3MNIAID NIH HHS R01 AI139179
Abstract
A series of 5-aryl-2-amino-
Indexed as
AntimalarialsFolic Acid AntagonistsMalariaMalaria, FalciparumAnimalsMiceMice, SCIDPlasmodium falciparumAntimalarialsFolic Acid Antagonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.